

Metabolism of chiral polychlorinated biphenyls by mammalian cytochrome P450 monoxygenases

Ito T¹, Miwa C¹, Haga Y², Goto E¹, Itoh T³, Yamamoto K⁴, Miise S¹, Matsumura C³, Nakano T⁵, Inui H^{1,5*}
 Grad. Sch. of Agr. Sci., Kobe Univ., Japan #1; Facul. of Agr., Kobe Univ., Japan #2 Hyogo Pref. Inst. of Environ. Sci., Japan #3; Lab. of Drug Design and Medic. Chem., Showa Pharm. Univ., Japan #4; Res. Cent. for Environ. Preserv., Osaka Univ., Japan #5; Biosignal Res. Cent., Kobe Univ., Japan #6 *hinui@kobe-u.ac.jp

Introduction
 Polychlorinated biphenyls (PCBs)
 • Low degradability
 • Biological concentration
 • Long distance mobility
 • Toxicity to humans and wildlife
 • Persistent organic pollutants (POPs)

Chiral PCBs
 • Three or four ortho-chlorine substituents
 • Steric hindrance of C-C bond
 • Rotational isomers (atropisomers)
 • Existence in the ratio of one to one (racemiser)

Enantioselective accumulation in human breast milk*

Mammalian cytochrome P450 monoxygenase
 • Monoxygenase reaction
 • Metabolism of PCBs^{2,3}

Detoxification

Toxicity evaluation toward each atropisomer of chiral PCBs

BACK NEXT

Metabolism of (±)-CB183 by human CYP2B6 and rat CYP2B1

Human CYP2B6
 (+)-CB183
 (-)-CB183

Rat CYP2B1
 (+)-CB183
 (-)-CB183

Human CYP2B6
 Hydroxylation activity (nmol/min/nmol P450)
 (+)-CB183
 (-)-CB183

3'-OH-CB183 (M1) 5-OH-CB183 (M2)

3'-MeO-CB183 (S1) 5-MeO-CB183 (S2)

BACK NEXT

Materials and Methods

Reaction condition
 40 pmol Human CYP2B6, Rat CYP2B1
 0.5 mM NADPH
 5 mM G6P
 1 U G6PDH
 3.3 mM MgCl₂
 100 mM Potassium phosphate buffer (pH7.4)
 0.8~6.4 μM (±)-CB45, CB91, CB135, CB183
 Total 0.5 ml Separated each atropisomer

- Start of the reaction by adding NADPH
- Incubation for 2 h at 37 °C
- Addition of the 50 ppb ¹³C-labeled OH-PCBs as the internal standards
- Methylation
- Analysis by high resolution gas chromatography and high resolution mass spectrometry
- Construction of docking models with P450s and PCBs

Detection of hydroxylated metabolites

Identification of metabolites for each atropisomer
 Clarification of the structural basis

CB45 (2,2',3,6-Tetrachlorobiphenyl)
 CB91 (2,2',3,4',6-Pentachlorobiphenyl)
 CB135 (2,2',3,3',5,6'-Hexachlorobiphenyl)
 CB183 (2,2',3,4,4',5',6'-Heptachlorobiphenyl)

BACK NEXT

Docking models of human CYP2B6 with (±)-CB183

Major conformation
 (+)-CB183

Minor conformation
 (-)-CB183

Hydroxylated metabolites
 (+)-CB183 < (-)-CB183
 Steric hindrance with (+)-CB183

Electrostatic potential
 High Lipophilicity Low

• Electron-rich 3-Cl ring
 • Location of 4-Cl ring in the lipophilic space
 • Approach of 3-Cl ring to the heme
 • 3'-position > 5-position

BACK NEXT

Metabolism of chiral PCBs by human CYP2B6 and rat CYP2B1

CB45
 Hydroxylation activity (nmol/min/nmol P450)
 (+)-CB45
 (-)-CB45

Human CYP2B6 Rat CYP2B1

CB91
 Hydroxylation activity (nmol/min/nmol P450)
 (+)-CB91
 (-)-CB91

Human CYP2B6 Rat CYP2B1

CB135
 Hydroxylation activity (nmol/min/nmol P450)
 (+)-CB135
 (-)-CB135

Human CYP2B6 Rat CYP2B1

Hydroxylation activity Human CYP2B6 << Rat CYP2B1
 Hydroxylation activity Human CYP2B6 < Rat CYP2B1
 Hydroxylation activity Human CYP2B6 < Rat CYP2B1

Hydroxylated metabolites (+)-CB45 > (-)-CB45
 Hydroxylated metabolites (+)-CB91 > (-)-CB91
 Hydroxylated metabolites (+)-CB135 > (-)-CB135

BACK NEXT

Summary and Conclusions

Proposed metabolic pathways of (±)-CB183

(±)-CB183 → 3'-OH-CB183 and 5-OH-CB183
 • Detection in rats administered by phenobarbital (CYP2B inducer)
 • Hydroxylated metabolites: (-)-CB183 > (+)-CB183
 • Accumulation of (+)-CB183 in human breast milk than (-)-CB183⁴
 • No metabolism by rat CYP2B1
 • The smaller cavity of rat CYP2B1 than that of human CYP2B6⁵

Difference of toxicity between each atropisomer of CB183 due to enantioselective metabolism

References
 1. Kanishi Y, Kakimoto K, Nagayoshi H, and Nakano T (2015), *Environmental Science and Pollution Research*, 23:2027-2032
 2. Inui H, Itoh T, Yamamoto K, Iwashiro S, and Sakaki T (2014), *International Journal of Molecular Sciences*, 15(8):14044-14057
 3. Uwimana E, Li X, and Lehmler H (2016) *Chemical Research in Toxicology*, 29:2108-2110
 4. Ohita C, Haraguchi K, Kato Y, Matsuoka M, Endo T, and Koga N (2007), *Organohalogen Compounds*, 69:1761-1764
 5. Miise S, Haga Y, Itoh T, Kato A, Fukuda I, Goto E, Yamamoto K, Yabu M, Matsumura C, Nakano T, Sakaki T, and Inui H (2016), *Toxicological Sciences*, 152(2):340-349

BACK NEXT